Comparative Pharmacology
Head-to-head clinical analysis: ISOPROTERENOL HYDROCHLORIDE versus NORISODRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPROTERENOL HYDROCHLORIDE versus NORISODRINE.
ISOPROTERENOL HYDROCHLORIDE vs NORISODRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-adrenergic agonist with non-selective affinity for β1 and β2 receptors; increases myocardial contractility, heart rate, and bronchodilation via Gs-protein activation and cAMP elevation.
Agonist at beta-1 and beta-2 adrenergic receptors, causing positive inotropic and chronotropic effects on the heart and bronchodilation.
Initial IV infusion: 0.5-5 mcg/min, titrated to heart rate and blood pressure; typical range 2-10 mcg/min. IV bolus: 10-20 mcg as needed. Continuous infusion: 0.01-0.5 mcg/kg/min (max 30 mcg/min).
Intravenous: 0.5-5 mcg/min continuous infusion; initial rate 0.5 mcg/min, titrate to effect. Subcutaneous or intramuscular: 0.2 mg (0.2 mL of 1:1000 solution).
None Documented
None Documented
Terminal elimination half-life is 2-3 minutes; clinically, catechol-O-methyltransferase (COMT)-mediated metabolism leads to rapid clearance.
Terminal half-life is 2-3 minutes; too short for sustained action, requiring continuous IV infusion.
Primarily renal excretion of sulfate conjugates and unchanged drug; biliary/fecal excretion is minimal.
Primarily renal excretion of unchanged drug (80-90%) and sulfate conjugates; minor biliary excretion (<5%).
Category C
Category C
Beta-Adrenergic Agonist
Beta-Adrenergic Agonist